# Danny Rischin

Source: https://onco.cc/people/danny-rischin/  
OnCo record `danny-rischin` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Melbourne oncologist who led C-POST, the trial that showed cemiplimab after surgery and radiotherapy cuts recurrence in high-risk cutaneous squamous-cell carcinoma.

## Summary

Danny Rischin directs medical oncology at the Peter MacCallum Cancer Centre and chairs head and neck trials for the Trans-Tasman Radiation Oncology Group. He was first author of the 2025 New England Journal of Medicine report of C-POST, in which adjuvant cemiplimab improved disease-free survival compared with placebo after surgery and radiotherapy for high-risk cutaneous squamous-cell carcinoma, and led the cemiplimab phase 2 programme in advanced disease.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: skin; head-and-neck; immunotherapy; trialist
- Role: Medical oncologist and Director of Medical Oncology, Peter MacCallum Cancer Centre
- Specialisms: Head and neck cancer; Cutaneous squamous-cell carcinoma; Chemoradiotherapy trials

## Connected records

- cancers: [Advanced cutaneous squamous cell carcinoma](https://onco.cc/cancers/advanced-cutaneous-scc/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)
- institutions: [Peter MacCallum Cancer Centre](https://onco.cc/institutions/peter-mac/)
- key papers: [C-POST: adjuvant cemiplimab versus placebo in high-risk cutaneous squamous cell carcinoma](https://onco.cc/key-papers/paper-c-post-adjuvant-cemiplimab-nejm-2025/)

---
JSON: https://onco.cc/api/v1/entities/danny-rischin.json